Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CPBIO Holding Co's Revenue for the
three
months ended in Dec. 2025 was $105.4 Mil. CPBIO Holding Co's average Accounts Receivable for the
three
months ended in Dec. 2025 was $130.9 Mil.
Hence, CPBIO Holding Co's Receivables Turnover for the
three
months ended in Dec. 2025 was 0.81.
CPBIO Holding Co (OTCPK:CAIHF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CPBIO Holding Co Receivables Turnover Related Terms
CPBIO Holding Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CPBIO Holding Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPBIO Holding Co (CAIHF) has a Receivables Turnover of 0.81 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CPBIO Holding Co and its competitors. According to the industry distribution chart, CPBIO Holding Co ranks #727 out of 950 companies in the Drug Manufacturers industry, placing it in the top 76.5%.
Is CPBIO Holding Co's Receivables Turnover too high?
CPBIO Holding Co's current Receivables Turnover is 0.81. The Drug Manufacturers industry median Receivables Turnover is 5.07. CPBIO Holding Co's value of 0.81 is 84% below this industry median. Based on the distribution chart, CPBIO Holding Co ranks #727 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CPBIO Holding Co has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #727 out of 950 companies for Receivables Turnover. This places CPBIO Holding Co in the lower half of its industry. The industry median Receivables Turnover is 5.07. CPBIO Holding Co's value of 0.81 is 84% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CPBIO Holding Co's current Receivables Turnover of 0.81 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current Receivables Turnover is 0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
CPBIO Holding Co (CAIHF) has a current Receivables Turnover of 0.81. The stock's GF Value™ is $0.14, compared to a current price of $0.28 — trading 100% above its estimated fair value. The current Receivables Turnover is 0.81 and 84% below the Drug Manufacturers industry median of 5.07. CPBIO Holding Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CPBIO Holding Co (CAIHF), the current Receivables Turnover is 0.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (CAIHF) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of $0.28 is trading 100% above its estimated GF Value™ of $0.14.
Key valuation signals for CAIHF:
Receivables Turnover: 0.81
GF Value™: $0.14 vs. price of $0.28 (100% above fair value)
Industry Position: 84% below the Drug Manufacturers median (#727 of 950)
No single metric tells the full story. See the CAIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score
Get the complete analysis for CAIHF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAIHF has been successfully added to your 
